90832 Federal Register / Vol. 89, No. 222 / Monday, November 18, 2024 / Notices 

POLICIES AND PRACTICES FOR STORAGE OF

RECORDS: 

Pre-existing paper and microfiche 

records were digitized. Input records are 

maintained digitally on electronic 

storage media in accordance with the 

safeguards below. 

POLICIES AND PRACTICES FOR RETRIEVAL OF

RECORDS: 

Records can be retrieved by name, 

SSN, employee IDs, organizational code, 

home address, or a combination of the 

information listed in the categories of 

records. 

POLICIES AND PRACTICES FOR RETENTION AND

DISPOSAL OF RECORDS: 

Records in the system are maintained 

in accordance with the following 

NARA’s records retention and 

schedules: General Records Schedule 

(GRS) 2.3, Employee Relations Records, 

Item 10, Employee relations programs’ 

administrative records, DAA–GRS– 

2018–0002–0001, Temporary. Destroy 

when 3 years old, but longer retention 

is authorized if required for business 

use; Item 40, Telework/alternate 

worksite program, DAA GRS–2018– 

0002–0004, Temporary. Destroy when 3 

years old, but longer retention is 

authorized if required for business use. 

GRS 2.4, Employee Compensation and 

Benefits Records, Item 10, Records used 

to calculate payroll, arrange paycheck 

deposit, and change previously issued 

paychecks, DAA–2018–0002–0001: 

Temporary. Destroy when 3 years old, 

but longer retention is authorized if 

required for business use. Item 30, Time 

and attendance records, DAAGRS– 

2019–0004–0002, Temporary, destroy 

when 3 years old, but longer retention 

is authorized if required for business 

use. Item 40, Agency payroll record for 

each pay period, DAA–GRS–2016– 

00015–0004, Destroy when 56 years old. 

GRS 4.2, Information Access, and 

Protection Records, Item 130, Personally 

identifiable information extracts, DAA– 

GRS–2013–0007–0012, Temporary. 

Destroy when 90 days old or no longer 

needed pursuant to supervisory 

authorization, whichever is appropriate. 

ADMINISTRATIVE, TECHNICAL, AND PHYSICAL

SAFEGUARDS: 

Administrative Procedures: Access to 

the records is limited to person(s) 

responsible for servicing the records in 

performance of their official duties, who 

are properly screened, trained on 

policies and procedures, and cleared for 

need to-know. Personnel who access the 

system and its data must take security 

awareness training and sign a Rules of 

Behavior initially (prior to access) and, 

at least, annually thereafter. Technical: 

Regular monitoring of users and the 

system are implemented to ensure only 

authorized personnel have access to 

information in the system. Strict 

controls are in place to minimize the 

compromise of stored or accessed in the 

system. Physical: The system and the 

data are housed in secure data center. 

RECORD ACCESS PROCEDURES: 

Individuals seeking access to records 

about themselves contained in this 

system should address inquiries to the 

System Manager at the address 

identified in ‘‘System Manager and 

Address’’ above. Request must be in 

writing, include SORN ID and name of 

this system of records notice, 

information on the Operating 

Administration-Department, specific 

date range and specific type of records 

seeking. Request must be signed by the 

requester, must be notarized as required 

by 28 U.S.C. 1746 in the following 

format: If executed without the United 

States: ‘‘I declare (or certify, verify, or 

state) under penalty of perjury under the 

laws of the United States of America 

that the foregoing is true and correct. 

Executed on (date). (Signature)’’. If 

executed within the United States, its 

territories, possessions, or 

commonwealths: ‘‘I declare (or certify, 

verify, or state) under penalty of perjury 

that the foregoing is true and correct. 

Executed on (date). (Signature)’’. 

CONTESTING RECORD PROCEDURES: 

See ‘‘Records Access Procedures’’ 

above. 

NOTIFICATION PROCEDURES: 

See ‘‘Records Access Procedures’’ 

above. 

EXEMPTIONS PROMULGATED FOR THE SYSTEM: 

None. 

HISTORY: 

A full notice of this system of records, 

DOT/ALL 11, Integrated Personnel 

Payroll System, was published in the 

Federal Register on November 7, 2008 

(73 FR 66285), April 11, 2000 (65 FR 

19845). 

Issued in Washington, DC. 

Karyn Gorman, 

Chief Privacy Officer. 

[FR Doc. 2024–26743 Filed 11–15–24; 8:45 am] 

BILLING CODE 4910–9X–P 

DEPARTMENT OF VETERANS 

AFFAIRS 

[OMB Control No. 2900–0890] 

Agency Information Collection Activity 

Under OMB Review: Industry Standard 

Forms for Completing an Appraisal 

Required by VA 

AGENCY: Veterans Benefits 

Administration, Department of Veterans 

Affairs. 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act (PRA) of 

1995, this notice announces that the 

Veterans Benefits Administration, 

Department of Veterans Affairs, will 

submit the collection of information 

abstracted below to the Office of 

Management and Budget (OMB) for 

review and comment. The PRA 

submission describes the nature of the 

information collection and its expected 

cost and burden and it includes the 

actual data collection instrument. 

DATES: Comments and 

recommendations for the proposed 

information collection should be sent by 

December 18, 2024. 

ADDRESSES: To submit comments and 

recommendations for the proposed 

information collection, please type the 

following link into your browser: 

www.reginfo.gov/public/do/PRAMain, 

select ‘‘Currently under Review—Open 

for Public Comments’’, then search the 

list for the information collection by 

Title or ‘‘OMB Control No. 2900–0890.’’ 

SUPPLEMENTARY INFORMATION: 

Title: Industry Standard Forms for 

Completing an Appraisal Required by 

VA FNMA Forms 1004, 1004C, 1004D, 

1004 (Desktop), 1025, 1073, 1075 and 

2055 

OMB Control Number: 2900–0890. 

Type of Review: Extension without 

change of a currently approved 

collection. 

Abstract: This information collection 

package seeks approval of VA’s 

requirement that appraisers utilize 

certain industry-standard forms in 

completing an appraisal. 38 U.S.C. 3731 

authorizes the VA Secretary to establish 

a panel of appraisers, prescribe 

qualifications for such appraisers, and 

determine reasonable value of a 

property, construction, repairs or 

alterations based on an appraisal report 

provided by a panel appraiser for the 

purpose of guaranteeing a loan. 

VA is requesting approval to 

authorize collection of these forms 

because accurate and thorough appraisal 

reporting is critical to the accuracy of 

underwriting for the mortgage process. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 222 / Monday, November 18, 2024 / Notices 90833 

Additionally, VA is looking to expand 

the list of authorized forms for use due 

to ongoing needs related to the 

pandemic. This collection of 

information provides a more thorough 

and complete appraisal of prospective 

VA-guaranteed properties ensuring that 

mortgages are acceptable for VA 

guarantee and thereby protect the 

interest of VA, taxpayers, and the 

Veterans Housing Benefit Program 

Fund. Policies and procedures for 

governing the VA appraisal program are 

set forth in Chapter 36, Title 38 of the 

CFR. 

An agency may not conduct or 

sponsor, and a person is not required to 

respond to a collection of information 

unless it displays a currently valid OMB 

control number. 

The Federal Register Notice with a 

60-day comment period soliciting 

comments on this collection of 

information was published at 89 FR 

73508, September 10, 2024. 

Affected Public: Individuals or 

Households. 

Estimated Annual Burden: 10,833. 

Estimated Average Burden per 

Respondent: 1 minute. 

Frequency of Response: One time. 

Estimated Number of Respondents: 

650,000. 

(Authority: 44 U.S.C. 3501 et seq.) 

Maribel Aponte, 

VA PRA Clearance Officer, Office of 

Enterprise and Integration, Data Governance 

Analytics, Department of Veterans Affairs. 

[FR Doc. 2024–26803 Filed 11–15–24; 8:45 am] 

BILLING CODE 8320–01–P 

DEPARTMENT OF VETERANS 

AFFAIRS 

Findings of Research MisconductC 

AGENCY: Department of Veterans Affairs. 

ACTION: Notice. 

SUMMARY: The Department of Veterans 

Affairs (VA), gives notice, pursuant to 

Veterans Health Administration (VHA) 

Directive 1058.02 ‘‘Research 

Misconduct’’ section 8.l, that the 

Department has made findings of 

research misconduct against Alan 

Lichtenstein, M.D. (‘‘Respondent’’), a 

former staff physician at the VA Greater 

Los Angeles Healthcare System, Los 

Angeles, CA. The Respondent did not 

appeal the findings or corrective actions 

against him. 

FOR FURTHER INFORMATION CONTACT: 

Shara Kabak, Research Misconduct 

Officer, Office of Research Oversight 

(10RO), 810 Vermont Avenue NW, 

Washington, DC 20420, (202) 632–7620 

(this is not a toll-free number). 

SUPPLEMENTARY INFORMATION: VA has 

made final findings of research 

misconduct against Alan Lichtenstein, 

M.D. (‘‘Respondent’’), a former staff 

physician at the VA Greater Los Angeles 

Healthcare System in Los Angeles, CA. 

Based on the recommended findings 

of a joint investigation conducted by VA 

Greater Los Angeles Healthcare System 

and University of California, Los 

Angeles School of Medicine, the 

Department found that the Respondent 

engaged in research misconduct by 

recklessly falsifying data included in at 

least ten of the following thirteen 

published papers: 

• DEPTOR is linked to a TORC1-p21 

survival proliferation pathway in 

multiple myeloma. Genes & Cancer. 

2014 Nov;5(11–12):407–19. doi: 

10.18632/genesandcancer.44 (hereafter, 

‘‘Genes Cancer 2014’’). 

• Cytotoxic properties of a DEPTORmTOR inhibitor in multiple myeloma 

cells. Cancer Research. 2016 Oct 

1;76(19):5822–5831. doi: 10.1158/0008– 

5472. CAN–16–1019 (hereafter, ‘‘Cancer 

Res. 2016’’). 

• Interleukin-6 activates 

phosphoinositol-3 kinase in multiple 

myeloma tumor cells by signaling 

through RAS-dependent and, separately, 

through p85-dependent pathways. 

Oncogene. 2004 Apr 22;23(19):3368–75. 

doi: 10.1038/sj.onc.1207459 (hereafter, 

‘‘Oncogene 2004’’). 

• MNK1-induced eIF–4E 

phosphorylation in myeloma cells: a 

pathway mediating IL–6-induced 

expansion and expression of genes 

involved in metabolic and proteotoxic 

responses. PLoS One. 2014 Apr 

8;9(4):e94011. doi: 10.1371/ 

journal.pone.0094011 (hereafter, ‘‘PLoS 

One 2014’’). Retraction in: PLoS One. 

2023 Sep 8;18(9):e0291491. doi: 

10.1371/journal.pone.0291491. 

• Mammalian target of rapamycin 

inhibitors activate the AKT kinase in 

multiple myeloma cells by up-regulating 

the insulin-like growth factor receptor/ 

insulin receptor substrate-1/ 

phosphatidylinositol 3-kinase cascade. 

Molecular Cancer Therapeutics. 2005 

Oct;4(10):1533–40. doi: 10.1158/1535– 

7163.MCT–05–0068 (hereafter, ‘‘Mol 

Cancer Ther. 2005’’). 

• Inhibition of SAPK2/p38 enhances 

sensitivity to mTORC1 inhibition by 

blocking IRES-mediated translation 

initiation in glioblastoma. Molecular 

Cancer Therapeutics. 2011 10:2244– 

2256 Dec;10(12):2244–56. doi: 10.1158/ 

1535–7163.MCT–11–0478 (hereafter, 

‘‘Mol Cancer Ther. 2011’’). 

• Specific blockade of Rictor-mTOR 

association inhibits mTORC2 activity 

and is cytotoxic in glioblastoma. PLoS 

One. 2017; Apr 28;12(4):e0176599. doi: 

10.1371/journal.pone.0176599 

(hereafter, ‘‘PLoS One 2017’’). 

Correction in: PLoS One. 2019 Feb 

6;14(2):e0212160. doi: 10.1371/ 

journal.pone.0212160. Retraction in: 

PLoS One. 2023 Sep 8;18(9):e0291490. 

doi: 10.1371/journal.pone.0291490. 

• MNK kinases facilitate c-myc IRES 

activity in rapamycin-treated multiple 

myeloma. Oncogene. 2013 Jan 

10;32(2):190–7. doi: 10.1038/ 

onc.2012.43 (hereafter, ‘‘Oncogene 

2013’’). Expression of Concern in: 

Oncogene. 2023 Oct;42(41):3088. doi: 

10.1038/s41388–023–02818–z. 

• The PP242 mammalian target of 

rapamycin (mTOR) inhibitor activates 

extracellular signal-regulated kinase 

(ERK) in multiple myeloma cells via a 

target of rapamycin complex 1 (TORC1)/ 

eukaryotic translation initiation factor 

4E (eIF–4E)/RAF pathway and 

activation is a mechanism of resistance. 

Journal of Biological Chemistry. 2012 

Jun 22;287(26):21796–805. doi: 10.1074/ 

jbc.M111.304626 (hereafter, ‘‘J Biol 

Chem. 2012’’). 

• Therapeutic potential of targeting 

IRES-dependent c-myc translation in 

multiple myeloma cells during ER 

stress. Oncogene. 2016 Feb 

25;35(8):1015–24. doi: 10.1038/ 

onc.2015.156 (hereafter, ‘‘Oncogene 

2016’’). Retraction in: Oncogene. 2023 

Sep;42(40):3016. doi: 10.1038/s41388– 

023–02820–5. 

• SGK kinase activity in multiple 

myeloma cells protects against ER stress 

apoptosis via a SEK-dependent 

mechanism. Molecular Cancer 

Research. 2016 Apr;14(4):397–407. doi: 

10.1158/1541–7786.MCR–15–0422 

(hereafter, ‘‘Mol Cancer Res. 2016’’). 

• A novel therapeutic induces 

DEPTOR degradation in multiple 

myeloma cells with resulting tumor 

cytotoxicity. Molecular Cancer 

Therapeutics. 2019 Oct;18(10):1822– 

1831. doi: 10.1158/1535–7163.MCT–19– 

0115 (hereafter, ‘‘Mol Cancer Ther. 

2019’’). 

• Downstream effectors of oncogenic 

ras in multiple myeloma cells. Blood. 

2003 Apr 15;101(8):3126–35. doi: 

10.1182/blood–2002–08–2640 

(hereafter, ‘‘Blood 2003’’). 

Specifically, the Department found 

that the Respondent recklessly 

committed research misconduct by 

reusing the same Western blot or kinase 

assay image to falsely represent the 

results related to the following pairs of 

experiments such that at least one of the 

sets of images in each of the pairs listed 

below is inaccurate: 

• p-4E–BP1–T37/46, p–4E–BP1–S65 

and Tubulin expression in Figure 3B of 

Genes Cancer 2014 and Figure 1F of 

Cancer Res. 2016. 


lotter on DSK11XQN23PROD with NOTICES1